Literature DB >> 16815690

In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data.

Min-Nan Hung1, Po-Ren Hsueh, Hou-Tai Chang, Wen-Sen Lee, Ming-Yuan Chou, Ing-Shen Chen, Jen-Hsien Wang, Chen-Fu Lin, Jainn-Ming Shyr, Wen-Chien Ko, Jiunn-Jong Wu, Yung-Ching Liu, Wen-Kuei Huang, Lee-Jene Teng, Cheng-Yi Liu, Kwen-Tay Luh.   

Abstract

We investigated the in vitro activity of various piperacillin and sulbactam combinations against Gram-negative bacterial isolates from Intensive Care Units (ICUs) in Taiwan. Antimicrobial susceptibility testing of 1030 bacterial isolates recovered from ICUs of nine major teaching hospitals was performed using the agar dilution method. Sulbactam was added to piperacillin either at a fixed sulbactam concentration of 4 mg/L and 8 mg/L or at a piperacillin:sulbactam ratio of 2:1 and 4:1. Piperacillin/sulbactam at a ratio of 2:1 or a fixed 8 mg/L concentration of sulbactam had better activities against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Serratia marcescens than other piperacillin/sulbactam formulations. For Pseudomonas aeruginosa, piperacillin/sulbactam (2:1 or 4:1 ratios) had MIC(90) values (minimum inhibitory concentration for 90% of the organisms) of 64 mg/L (>90% susceptibility) compared with 64 mg/L for cefoperazone/sulbactam (68% susceptibility) and 128 mg/L for piperacillin/tazobactam (82% susceptibility). For Acinetobacter baumannii, both piperacillin/sulbactam (either 2:1 ratio or a fixed 8 mg/L sulbactam) and cefoperazone/sulbactam were the most potent agents. Adding sulbactam to piperacillin resulted in increased susceptibility rates among piperacillin-resistant P. aeruginosa (53-57% in either 2:1 or 4:1 ratios) and A. baumannii (38-46% in either 2:1 ratio or a fixed 8 mg/L concentration of sulbactam) isolates. Results of susceptibility tests with piperacillin/sulbactam are dependent on the method used. Piperacillin/sulbactam combinations possessed better in vitro activities than piperacillin alone or piperacillin/tazobactam against P. aeruginosa and A. baumannii.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16815690     DOI: 10.1016/j.ijantimicag.2006.02.017

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  4 in total

1.  Pharmacist interventions on antibiotic use in inpatients with respiratory tract infections in a Chinese hospital.

Authors:  Jian Shen; Qingmin Sun; Xianmei Zhou; Yu Wei; Yongjian Qi; Jiping Zhu; Tingting Yan
Journal:  Int J Clin Pharm       Date:  2011-11-09

2.  Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms.

Authors:  Chih-Cheng Lai; Chi-Chung Chen; Ying-Chen Lu; Tsuey-Pin Lin; Yin-Ching Chuang; Hung-Jen Tang
Journal:  Infect Drug Resist       Date:  2018-09-11       Impact factor: 4.003

3.  Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).

Authors:  Chih-Cheng Lai; Ying-Sheng Chen; Nan-Yao Lee; Hung-Jen Tang; Susan Shin-Jung Lee; Chin-Fu Lin; Po-Liang Lu; Jiunn-Jong Wu; Wen-Chien Ko; Wen-Sen Lee; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2019-03-14       Impact factor: 4.003

4.  In Vitro Activity of Various Sulbactam Compounds and Piperacillin/Tazobactam against Clinical Isolates of Different Gram-Negative Bacteria.

Authors:  Shunian Xiao; Chuyue Zhuo; Chao Zhuo
Journal:  Comput Math Methods Med       Date:  2021-11-25       Impact factor: 2.238

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.